Loading company financials…
NASDAQ NMS - GLOBAL MARKET · Biotechnology · CIK 0001082554
$563.49
+1.74% · delayed ~15 min
Last price from Oct 21, 2026
$24.59B market value
From UNITED THERAPEUTICS Corp's FY2025 10-K, filed Feb 25, 2026 · read the filing
UNITED THERAPEUTICS develops and makes medicines. It took in $3.18B last year, which makes it a mid-sized company. Of every dollar it sells, about 42 cents is left as profit.
The financial picture is led by profitability and debt, with growth worth watching.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Financial health
Strong finances across the board.
From UNITED THERAPEUTICS Corp's FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Capital spending
$246.5M → $520.5M
Revenue
$2.88B → $3.18B
Gross profit
$2.57B → $2.80B
Operating income
$1.38B → $1.49B
Measured against FY2024, from the 10-K filed Feb 25, 2026
Changed: +111.2%
$246.5M to $520.5MCritical
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
How the latest move compares (quote delayed ~15 min), and what was published around it
UTHR rose 1.74% on the latest quote. The average Health Care company tracked here moved +1.62%, and the S&P 500 −1.04%. That is in line with its sector and 2.8 points above the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 7% a year for the next 10 years. Over the last 10 years it grew by about 12% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 42 cents of every dollar of sales as profit, earning $1.33B last year.
Slowly. Sales grew 10.6% last year.
It does not appear so. For every $1 it owes, it owns $10.05 in assets.
Core operating and valuation reference metrics
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it earned $1.33B and generated $1.56B of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 25, 2026Filing for FY2025 | FY202410-K · Feb 26, 2025Filing for FY2024 | FY202310-K · Feb 21, 2024Filing for FY2023 | FY202210-K · Feb 21, 2024Filing for FY2022 | FY202110-K · Feb 21, 2024Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $3.18B | $2.88B | $2.33B | $1.94B | $1.69B | +10.6% |
| Cost of revenue | $384.4M | $309.7M | $257.5M | $151.6M | $122.5M | +24.1% |
| Gross profit | $2.80B | $2.57B | $2.07B | $1.78B | $1.56B | +9.0% |
| Gross marginGross profit ÷ revenueWhat is this? | 87.9% | 89.2% | 88.9% | 92.2% | 92.7% | −1.3 pts |
| Selling, general and administrative | $755.8M | $709.7M | $477.1M | $482.1M | $467.0M | +6.5% |
| Operating income | $1.49B | $1.38B | $1.18B | $979.7M | $555.9M | +8.4% |
| Operating marginOperating income ÷ revenueWhat is this? | 46.9% | 47.9% | 50.9% | 50.6% | 33.0% | −1.0 pts |
| Interest expense | $19.5M | $42.9M | $59.3M | $32.4M | $18.6M | −54.5% |
| Income before tax | $1.71B | $1.54B | $1.27B | $950.6M | $593.9M | +11.4% |
| Net income | $1.33B | $1.20B | $984.8M | $727.3M | $475.8M | +11.7% |
| Net marginNet income ÷ revenueWhat is this? | 41.9% | 41.5% | 42.3% | 37.6% | 28.2% | +0.4 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $30.58 | $26.66 | $20.94 | $15.80 | $10.55 | +14.7% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| UTHRUNITED THERAPEUTICS Corp · this page | 8.7/10 | 7/8 |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Exercised stock options — 9,500 shares at $117.76 ($1.1M)
Holds 333,943 shares after this filing.
Sold on the open market — 46 shares at $552.52 ($25.4K)
Holds 333,897 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Reported another event
Read the filingReported another event
Read the filingWrite down why you are following UNITED THERAPEUTICS Corp, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
Coverage from the last 30 days
United Therapeutics' Tyvaso Outlook Faces Near-Term Pressure After Liquidia Settlement, RBC Says
Yahoo Finance ·
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Yahoo Finance ·
United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026
Yahoo Finance ·
United Therapeutics (UTHR): Can the Profit-Machine Biotech Finally Crack the S&P 500?
Yahoo Finance ·
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from UTHR's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 25, 2026), reported under the US GAAP taxonomy. View the source filing.
3 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. Accounting had too few reported figures and is left out of the average rather than counted as a weakness, so a company is never marked down for a figure it did not publish. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 8 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 8.7 | 7/8 | 10-K, filed Feb 25, 2026 |
| FY2024 | 10.0 | 8/8 | 10-K, filed Feb 26, 2025 |
| FY2023 | 10.0 | 4/8 | 10-K, filed Feb 21, 2024 |
| FY2022 | 8.7 | 5/8 | 10-K, filed Feb 22, 2023 |
| FY2021 | 8.7 | 7/8 | 10-K, filed Feb 24, 2022 |
| FY2020 | 8.7 | 7/8 | 10-K, filed Feb 24, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
7 of 8 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's. One could not be evaluated and is excluded from the total rather than counted as a failure.
21.85
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
not reported — This company has not reported enough of the required figures to calculate this score.
This company has not reported enough of the required figures to calculate this score.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: +10.6%
$2.88B to $3.18BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +9.0%
$2.57B to $2.80BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +8.4%
$1.38B to $1.49BNotable
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +11.7%
$1.20B to $1.33BNotable
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: −1.3 pts
89.2% to 87.9%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Improved: +14.7%
$26.66 to $30.58Notable
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: -8.3%
$1.70B to $1.56BNotable
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: -2.7%
44.8M to 43.6MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Aug 5, 2026 — read it.
Deteriorated: −3.4 pts
45.6% to 42.2%Significant
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +3.8 pts
38.8% to 42.5%Significant
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: -5.6%
45.2M to 42.7MSignificant
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Deteriorated: -9.2%
$364.5M to $330.8MNotable
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +7.6%
$309.5M to $333.0MNotable
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: −1.7 pts
89.0% to 87.3%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Improved: +14.0%
$6.85 to $7.80Notable
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +13.2%
$1.59B to $1.80BNotable
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Aug 5, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Improved: +40.9%
$1.28B to $1.80BCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +21.1%
$274.9M to $333.0MSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +4.4 pts
82.9% to 87.3%Significant
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Improved: +7.3 pts
35.2% to 42.5%Significant
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: +19.7%
$6.52 to $7.80Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +5.5%
$648.1M to $683.8MNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Deteriorated: +1.2%
42.2M to 42.7MNotable
Why it matters: New shares divide the same company into more pieces, so each existing holding owns slightly less of it. Often pay for staff or an acquisition rather than anything wrong.
3 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 5% and 9%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Opinions from 22 analysts covering this company, as of . Their views, not this site's.
Of 22 analysts publishing on this company, 6 say strong buy, 11 say buy, 4 say hold and 1 say sell. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 8.2% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 19.6x — investors pay $19.6 for each $1 of trailing profit.
This company has not reported enough of the required figures to calculate this score.
| 10.6% |
| 41.9% |
| 18.43x |
| 0.11x |
| BIIBBIOGEN INC. | 9.0/10 | 6/9 | 2.2% | 13.1% | 28.82x | 0.61x |
|---|
| ALNYALNYLAM PHARMACEUTICALS, INC. | 7.3/10 | 5/8 | 65.2% | 8.4% | 95.89x | 5.29x |
|---|
| INCYINCYTE CORP | 10.0/10 | 6/8 | 21.2% | 25.0% | 18.04x | 0.35x |
|---|
| Median of peers | 9.0/10 | — | 21.2% | 13.1% | 28.82x | 0.61x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Sold on the open market — 194 shares at $553.78 ($107.4K)
Holds 333,703 shares after this filing.
Sold on the open market — 550 shares at $555.19 ($305.4K)
Holds 333,153 shares after this filing.
Sold on the open market — 567 shares at $556.41 ($315.5K)
Holds 332,586 shares after this filing.
Sold on the open market — 1,702 shares at $557.25 ($948.4K)
Holds 330,884 shares after this filing.
Sold on the open market — 1,137 shares at $558.32 ($634.8K)
Holds 329,747 shares after this filing.
Sold on the open market — 743 shares at $559.25 ($415.5K)
Holds 329,004 shares after this filing.
Sold on the open market — 820 shares at $560.50 ($459.6K)
Holds 328,184 shares after this filing.
Sold on the open market — 200 shares at $561.44 ($112.3K)
Holds 327,984 shares after this filing.
Sold on the open market — 960 shares at $562.54 ($540.0K)
Holds 327,024 shares after this filing.
Sold on the open market — 1,253 shares at $563.43 ($706.0K)
Holds 325,771 shares after this filing.
Sold on the open market — 768 shares at $564.63 ($433.6K)
Holds 325,003 shares after this filing.
Sold on the open market — 480 shares at $565.36 ($271.4K)
Holds 324,523 shares after this filing.
Sold on the open market — 80 shares at $566.43 ($45.3K)
Holds 324,443 shares after this filing.
Exercised stock options — 9,500 shares at $117.76 ($1.1M)
Holds 333,943 shares after this filing.
Sold on the open market — 117 shares at $546.84 ($64.0K)
Holds 333,826 shares after this filing.
Sold on the open market — 575 shares at $547.79 ($315.0K)
Holds 333,251 shares after this filing.
Sold on the open market — 948 shares at $548.95 ($520.4K)
Holds 332,303 shares after this filing.
Sold on the open market — 586 shares at $550.02 ($322.3K)
Holds 331,717 shares after this filing.
Sold on the open market — 1,134 shares at $551.03 ($624.9K)
Holds 330,583 shares after this filing.
Sold on the open market — 1,560 shares at $551.85 ($860.9K)
Holds 329,023 shares after this filing.
Sold on the open market — 240 shares at $553.14 ($132.8K)
Holds 328,783 shares after this filing.
Sold on the open market — 1,260 shares at $553.97 ($698.0K)
Holds 327,523 shares after this filing.
Sold on the open market — 160 shares at $555.09 ($88.8K)
Holds 327,363 shares after this filing.
Sold on the open market — 440 shares at $556.06 ($244.7K)
Holds 326,923 shares after this filing.
Sold on the open market — 320 shares at $557.12 ($178.3K)
Holds 326,603 shares after this filing.
Sold on the open market — 520 shares at $558.72 ($290.5K)
Holds 326,083 shares after this filing.
Sold on the open market — 280 shares at $559.70 ($156.7K)
Holds 325,803 shares after this filing.
Sold on the open market — 315 shares at $560.67 ($176.6K)
Holds 325,488 shares after this filing.
Sold on the open market — 360 shares at $561.84 ($202.3K)
Holds 325,128 shares after this filing.
Sold on the open market — 464 shares at $562.78 ($261.1K)
Holds 324,664 shares after this filing.
Sold on the open market — 221 shares at $563.56 ($124.5K)
Holds 324,443 shares after this filing.
Exercised stock options — 9,500 shares at $117.76 ($1.1M)
Holds 333,943 shares after this filing.
Sold on the open market — 160 shares at $534.75 ($85.6K)
Holds 333,783 shares after this filing.
Sold on the open market — 360 shares at $536.36 ($193.1K)
Holds 333,423 shares after this filing.
Sold on the open market — 240 shares at $537.11 ($128.9K)
Holds 333,183 shares after this filing.
Sold on the open market — 160 shares at $538.54 ($86.2K)
Holds 333,023 shares after this filing.
Sold on the open market — 880 shares at $539.79 ($475.0K)
Holds 332,143 shares after this filing.
Sold on the open market — 1,800 shares at $540.63 ($973.1K)
Holds 330,343 shares after this filing.
Sold on the open market — 520 shares at $541.38 ($281.5K)
Holds 329,823 shares after this filing.
Sold on the open market — 260 shares at $542.81 ($141.1K)
Holds 329,563 shares after this filing.
Sold on the open market — 1,240 shares at $543.73 ($674.2K)
Holds 328,323 shares after this filing.
Sold on the open market — 1,040 shares at $544.89 ($566.7K)
Holds 327,283 shares after this filing.
Sold on the open market — 1,065 shares at $545.90 ($581.4K)
Holds 326,218 shares after this filing.
Sold on the open market — 416 shares at $547.00 ($227.6K)
Holds 325,802 shares after this filing.
Sold on the open market — 559 shares at $547.98 ($306.3K)
Holds 325,243 shares after this filing.
Sold on the open market — 360 shares at $549.01 ($197.6K)
Holds 324,883 shares after this filing.
Sold on the open market — 120 shares at $549.66 ($66.0K)
Holds 324,763 shares after this filing.
Sold on the open market — 80 shares at $551.77 ($44.1K)
Holds 324,683 shares after this filing.
Sold on the open market — 40 shares at $552.78 ($22.1K)
Holds 324,643 shares after this filing.
Sold on the open market — 120 shares at $554.00 ($66.5K)
Holds 324,523 shares after this filing.
Sold on the open market — 80 shares at $556.88 ($44.5K)
Holds 324,443 shares after this filing.
Exercised stock options — 9,500 shares at $117.76 ($1.1M)
Holds 333,943 shares after this filing.
Sold on the open market — 240 shares at $530.48 ($127.3K)
Holds 333,703 shares after this filing.
Sold on the open market — 1,024 shares at $531.54 ($544.3K)
Holds 332,679 shares after this filing.
Sold on the open market — 2,378 shares at $532.46 ($1.3M)
Holds 330,301 shares after this filing.
Sold on the open market — 1,818 shares at $533.32 ($969.6K)
Holds 328,483 shares after this filing.
Sold on the open market — 640 shares at $534.41 ($342.0K)
Holds 327,843 shares after this filing.
Sold on the open market — 535 shares at $535.67 ($286.6K)
Holds 327,308 shares after this filing.
Sold on the open market — 865 shares at $536.66 ($464.2K)
Holds 326,443 shares after this filing.
Sold on the open market — 760 shares at $537.74 ($408.7K)
Holds 325,683 shares after this filing.
Sold on the open market — 401 shares at $538.55 ($216.0K)
Holds 325,282 shares after this filing.
Sold on the open market — 239 shares at $539.60 ($129.0K)
Holds 325,043 shares after this filing.
Sold on the open market — 169 shares at $541.62 ($91.5K)
Holds 324,874 shares after this filing.
Sold on the open market — 391 shares at $542.67 ($212.2K)
Holds 324,483 shares after this filing.
Sold on the open market — 40 shares at $543.85 ($21.8K)
Holds 324,443 shares after this filing.
Exercised stock options — 8,300 shares at $146.03 ($1.2M)
Holds 53,472 shares after this filing.
Sold on the open market — 268 shares at $541.64 ($145.2K)
Holds 53,204 shares after this filing.
Sold on the open market — 1,924 shares at $542.49 ($1.0M)
Holds 51,280 shares after this filing.
Sold on the open market — 1,983 shares at $543.56 ($1.1M)
Holds 49,297 shares after this filing.
Sold on the open market — 791 shares at $544.85 ($431.0K)
Holds 48,506 shares after this filing.
Sold on the open market — 2,615 shares at $545.69 ($1.4M)
Holds 45,891 shares after this filing.
Sold on the open market — 719 shares at $546.56 ($393.0K)
Holds 45,172 shares after this filing.
Exercised stock options — 9,500 shares at $117.76 ($1.1M)
Holds 333,943 shares after this filing.
Sold on the open market — 281 shares at $540.48 ($151.9K)
Holds 333,662 shares after this filing.
Sold on the open market — 1,163 shares at $541.59 ($629.9K)
Holds 332,499 shares after this filing.
Sold on the open market — 456 shares at $542.68 ($247.5K)
Holds 332,043 shares after this filing.
Sold on the open market — 371 shares at $543.39 ($201.6K)
Holds 331,672 shares after this filing.
Sold on the open market — 269 shares at $544.75 ($146.5K)
Holds 331,403 shares after this filing.
Sold on the open market — 825 shares at $545.87 ($450.3K)
Holds 330,578 shares after this filing.
Sold on the open market — 601 shares at $546.94 ($328.7K)
Holds 329,977 shares after this filing.
Sold on the open market — 2,166 shares at $547.83 ($1.2M)
Holds 327,811 shares after this filing.
Sold on the open market — 2,039 shares at $548.89 ($1.1M)
Holds 325,772 shares after this filing.
Sold on the open market — 1,009 shares at $549.76 ($554.7K)
Holds 324,763 shares after this filing.
Sold on the open market — 200 shares at $550.72 ($110.1K)
Holds 324,563 shares after this filing.
Sold on the open market — 120 shares at $551.50 ($66.2K)
Holds 324,443 shares after this filing.
Exercised stock options — 9,500 shares at $117.76 ($1.1M)
Holds 333,943 shares after this filing.
Sold on the open market — 40 shares at $526.07 ($21.0K)
Holds 333,903 shares after this filing.
Sold on the open market — 160 shares at $530.09 ($84.8K)
Holds 333,743 shares after this filing.
Sold on the open market — 120 shares at $531.19 ($63.7K)
Holds 333,623 shares after this filing.
Sold on the open market — 40 shares at $532.48 ($21.3K)
Holds 333,583 shares after this filing.
Sold on the open market — 240 shares at $534.63 ($128.3K)
Holds 333,343 shares after this filing.
Sold on the open market — 400 shares at $535.89 ($214.4K)
Holds 332,943 shares after this filing.
Sold on the open market — 633 shares at $537.19 ($340.0K)
Holds 332,310 shares after this filing.
Sold on the open market — 1,127 shares at $538.00 ($606.3K)
Holds 331,183 shares after this filing.
Sold on the open market — 525 shares at $539.09 ($283.0K)
Holds 330,658 shares after this filing.
Sold on the open market — 2,002 shares at $540.23 ($1.1M)
Holds 328,656 shares after this filing.
Sold on the open market — 1,930 shares at $541.20 ($1.0M)
Holds 326,726 shares after this filing.
Sold on the open market — 883 shares at $542.07 ($478.6K)
Holds 325,843 shares after this filing.
Sold on the open market — 400 shares at $543.15 ($217.3K)
Holds 325,443 shares after this filing.
Sold on the open market — 480 shares at $544.35 ($261.3K)
Holds 324,963 shares after this filing.
Sold on the open market — 480 shares at $545.48 ($261.8K)
Holds 324,483 shares after this filing.
Sold on the open market — 40 shares at $546.00 ($21.8K)
Holds 324,443 shares after this filing.
Exercised stock options — 9,500 shares at $117.76 ($1.1M)
Holds 333,943 shares after this filing.
Sold on the open market — 639 shares at $542.76 ($346.8K)
Holds 333,304 shares after this filing.
Sold on the open market — 2,340 shares at $543.48 ($1.3M)
Holds 330,964 shares after this filing.
Sold on the open market — 1,492 shares at $544.56 ($812.5K)
Holds 329,472 shares after this filing.
Sold on the open market — 1,507 shares at $545.52 ($822.1K)
Holds 327,965 shares after this filing.
Sold on the open market — 1,452 shares at $546.46 ($793.5K)
Holds 326,513 shares after this filing.
Sold on the open market — 630 shares at $547.47 ($344.9K)
Holds 325,883 shares after this filing.
Sold on the open market — 698 shares at $548.49 ($382.8K)
Holds 325,185 shares after this filing.
Sold on the open market — 502 shares at $549.47 ($275.8K)
Holds 324,683 shares after this filing.
Sold on the open market — 160 shares at $550.59 ($88.1K)
Holds 324,523 shares after this filing.
Sold on the open market — 80 shares at $551.49 ($44.1K)
Holds 324,443 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 8,300 shares ($4.5M) on or after .
Shares originally obtained via Stock Option Exercise.
Filed notice to sell 8,300 shares ($4.7M) on or after .
Shares originally obtained via Stock Option Exercise.
Filed notice to sell 209,000 shares ($113.3M) on or after .
Shares originally obtained via Exercise of Stock Options.
Filed notice to sell 8,300 shares ($4.1M) on or after .
Shares originally obtained via Stock Option Exercise.
Filed notice to sell 228 shares ($115.3K) on or after .
Shares originally obtained via Stock Option Exercise.
Filed notice to sell 8,300 shares ($4.0M) on or after .
Shares originally obtained via Stock Option Exercise.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Signed a material agreement · Made a Regulation FD disclosure
Published results
Read the filingQuarterly report for Q2 FY2026
Operating margin −3.4 pts · Profit margin +3.8 pts · Shares in issue -5.6% — against Q2 FY2025
Read the filingHad a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingHad a director or senior officer leave or join · Held a shareholder vote
Read the filingPublished results
Read the filingQuarterly report for Q1 FY2026
Operating margin −6.5 pts · Gross margin −5.4 pts · Profit margin −5.4 pts — against Q1 FY2025
Read the filingProxy statement for a shareholder meeting
Read the filingReported another event
Read the filingSigned a material agreement · Made a Regulation FD disclosure
Read the filingMade a Regulation FD disclosure
Read the filingPublished results
Read the filingAnnual report for FY2025
Revenue +10.6% · Capital spending +111.2% · Gross profit +9.0% — against FY2024
Read the filingHad a director or senior officer leave or join · Amended its charter or changed its financial year · Made a Regulation FD disclosure
Read the filingPublished results
Read the filingQuarterly report for Q3 FY2025
Revenue +6.8% · Operating margin +2.8 pts · Operating income +13.2% — against Q3 FY2024
Read the filingReported another event
Read the filingSigned a material agreement · Made a Regulation FD disclosure
Read the filingPrimary sources and further research